Restoring blood coagulation in patients
taking Factor Xa Direct Oral Anticoagulants
(FXa-DOACs)

Our focus lies in the development of a breakthrough, swift-acting, and convenient universal bypassing agent that restores blood coagulation in patients taking Factor Xa Direct Oral Anticoagulants (FXa-DOACs).

We aim to stop severe bleeding and eliminate bleeding risk during surgery in patients taking FXa DOACs.